Del-1 Therapeutics

Del-1 Therapeutics is a biotechnology company focused on developing novel therapies that leverage the anti-inflammatory and pro-resolving properties of the Developmental Endothelial Locus-1 (Del-1) protein. Founded by leading researchers George Hajishengallis and Triantafyllos Chavakis, the company aims to treat a variety of chronic inflammatory and autoimmune conditions, including periodontitis and multiple sclerosis. Their approach centers on utilizing Del-1 to regulate leukocyte recruitment and promote the resolution of inflammation. By targeting the underlying mechanisms of inflammatory tissue destruction, Del-1 Therapeutics seeks to provide transformative treatments for diseases with high unmet medical needs. The company's research is rooted in extensive academic collaboration and pioneering studies on the homeostatic role of Del-1 in various organ systems.